CCRM
Ksenia Bezverbnaya, PhD, is a skilled professional in technology and venture development, currently serving as Manager at CCRM since December 2021, having previously held roles as Senior Venture Associate and Venture Associate II. Ksenia's experience includes a Fellowship at Amplitude Ventures, where venture creation opportunities were identified in the biotech sector, and a PhD in Medical Sciences from McMaster University, focusing on cancer treatment through genetic engineering of T cells. Ksenia has a strong background in research, supervision of undergraduate students, and active participation in workshops and consulting projects, demonstrating a commitment to education and healthcare advancement.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.